These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 38216431)

  • 21. d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders.
    De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G
    Prog Brain Res; 2018; 242():69-96. PubMed ID: 30471683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action.
    Canal CE
    Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Magic Mushrooms - an exploratory look at how mental health professionals feel and think about Psilocybin.
    Meyer TD; Meir P; Lex C; Soares JC
    Psychiatry Res; 2022 Oct; 316():114727. PubMed ID: 35878481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained effects of single doses of classical psychedelics in humans.
    Knudsen GM
    Neuropsychopharmacology; 2023 Jan; 48(1):145-150. PubMed ID: 35729252
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic perceptions: mental health service user attitudes to psilocybin therapy.
    Corrigan K; Haran M; McCandliss C; McManus R; Cleary S; Trant R; Kelly Y; Ledden K; Rush G; O'Keane V; Kelly JR
    Ir J Med Sci; 2022 Jun; 191(3):1385-1397. PubMed ID: 34131812
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.
    Ortiz CE; Dourron HM; Sweat NW; Garcia-Romeu A; MacCarthy S; Anderson BT; Hendricks PS
    Neuropharmacology; 2022 Aug; 214():109127. PubMed ID: 35577136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psilocybin for the Treatment of Obsessive-Compulsive Disorders.
    Ehrmann K; Allen JJB; Moreno FA
    Curr Top Behav Neurosci; 2022; 56():247-259. PubMed ID: 34784024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the psychedelic experience an essential aspect of the therapeutic effect of serotonergic psychedelics? Conceptual, discovery, development and implementation implications for psilocybin and related agents.
    McIntyre RS
    Expert Opin Drug Saf; 2023; 22(10):885-889. PubMed ID: 37635320
    [No Abstract]   [Full Text] [Related]  

  • 31. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Treatment with psilocybin: applications for patients with psychiatric disorders].
    Breeksema JJ; Koolen MHB; Somers M; Schoevers RA
    Ned Tijdschr Geneeskd; 2021 Jan; 165():. PubMed ID: 33560605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Up-to-Date on clinical and preclinical studies of psilocybin therapy].
    Ibi D
    Nihon Yakurigaku Zasshi; 2024; 159(4):214-218. PubMed ID: 38945903
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The possible place for psychedelics in pharmacotherapy of mental disorders.
    Wojtas A
    Pharmacol Rep; 2023 Dec; 75(6):1313-1325. PubMed ID: 37934320
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders.
    Thomas K; Malcolm B; Lastra D
    J Psychoactive Drugs; 2017; 49(5):446-455. PubMed ID: 28481178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Classic psychedelic drugs and their potential therapeutic effect].
    Bayat M
    Ugeskr Laeger; 2017 Sep; 179(37):. PubMed ID: 28918777
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Potential of Psychedelics for the Treatment of Episodic Migraine.
    Schindler EAD
    Curr Pain Headache Rep; 2023 Sep; 27(9):489-495. PubMed ID: 37540398
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The zebrafish for preclinical psilocybin research.
    Syed OA; Tsang B; Gerlai R
    Neurosci Biobehav Rev; 2023 Oct; 153():105381. PubMed ID: 37689090
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.